
CAS · 137525-51-0
BPC-157 + TB-500 Blend 20mg
Buy BPC-157 + TB-500 Blend 20mg online — research-grade lyophilized peptide for laboratory use. Body Protection Compound-157 (15-amino-acid pentadecapeptide). ≥98% HPLC purity verified.

Plate № PG-1004 — Reykjavík
Figure i · IGF-1 LR3 1mg — lyophilized plate
№ 01 — Monograph
Long Arg3 IGF-1 — extended half-life insulin-like growth factor analog (20–30 hours vs 12–15 minutes for native IGF-1). IGFBP-independent. Researched for satellite cell activation and muscle protein synthesis.
Priced from
$71.99
Purity
≥ 98%
HPLC verified
Form
Lyophilized
Sealed vial
Ship
2–5 days
US, tracked
№ 02 — Specifications
CAS · 946870-92-4№ 03 — Mechanism
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1, CAS: 946870-92-4) is a recombinant analog of native IGF-1 with two structural modifications: an N-terminal 13-amino acid extension and an Arg substitution at position 3 (replacing glutamic acid). These modifications reduce IGFBP (IGF binding protein) affinity by >1000-fold. Native IGF-1 is >99% bound to IGFBPs in circulation, limiting bioavailability and producing a 12–15 minute half-life. IGF-1 LR3 remains in free, active form with a half-life of approximately 20–30 hours — a 100x increase. It activates the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase, driving the PI3K/Akt/mTOR pathway (protein synthesis, cell growth, survival) and Ras/MAPK pathway (proliferation, differentiation). IGF-1R is expressed on virtually every cell type. Molecular weight: ~9,117 Da.
№ 04 — Highlights
The defining feature of IGF-1 LR3 is its near-complete independence from IGF binding proteins. Native IGF-1 is >99% bound to IGFBPs in circulation. IGF-1 LR3's position 3 arginine substitution reduces IGFBP-3 binding affinity by >1000-fold, allowing the analog to remain in free, active form — enabling research on unrestrained IGF-1R signaling.
IGF-1 is the primary activator of muscle satellite cells — the stem cell population responsible for muscle regeneration and hypertrophy. Satellite cells express IGF-1R and respond to IGF-1 by exiting quiescence, proliferating, and differentiating into myoblasts. IGF-1 LR3's extended half-life makes it practical for sustained satellite cell activation studies.
IGF-1R activation drives the PI3K/Akt/mTOR signaling cascade — the central anabolic pathway in mammalian biology. mTORC1 activation downstream of Akt stimulates protein synthesis via S6K1 and 4E-BP1, promotes ribosome biogenesis, and inhibits autophagy. IGF-1 LR3's extended activity window enables sustained mTOR pathway research.
№ 05 — Correspondence
The letters we receive most frequently about this compound, with plain answers.
IGF-1 LR3 has a position 3 arginine substitution and N-terminal extension that reduce IGFBP binding affinity by >1000x. This extends half-life from 12–15 minutes to 20–30 hours and allows the peptide to remain in free, active form rather than bound to carrier proteins.
Yes — BPC-157 improves local blood flow and removes inflammatory barriers to recovery; TB-500 drives systemic cell migration; IGF-1 LR3 activates mTOR-driven protein synthesis and satellite cells. Together they address the vascular, cellular, and anabolic aspects of tissue repair research.
Reconstitute with 0.1% acetic acid (1mg in 1mL = 1mg/mL), or bacteriostatic water with 0.1% BSA carrier to stabilize the protein. Swirl gently — do not shake. Store at 2–8°C, use within 3–4 weeks.
Laboratory Use Only. This compound is sold for in-vitro laboratory research and is not intended for human consumption, injection, or therapeutic use. Nothing on this page constitutes medical advice. Researchers are responsible for compliance with applicable regulations in their jurisdiction.
№ 06 — From the catalog

CAS · 137525-51-0
Buy BPC-157 + TB-500 Blend 20mg online — research-grade lyophilized peptide for laboratory use. Body Protection Compound-157 (15-amino-acid pentadecapeptide). ≥98% HPLC purity verified.
IGF-1 LR3 1mg
$71.99